Kineta Inc

NASDAQ:KAUnited States

Kineta, Inc., formerly Yumanity Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. The Company's immuno-oncology focused PiiONEER Platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets developed through the PiiONEER Platform includes KVA12123, a monoclonal antibody (mAb) immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment.

Contact Information

Headquarters

219 Terry Ave. N., Suite 300SEATTLE, WA, United States 98109

Phone

206-378-0400

Fax

302-636-5454

Executives

President

Craig Philips

Chief Executive Officer, Director

Shawn Iadonato

Chief Financial Officer

Keith Baker

Chief Scientific Officer

Thierry Guillaudeux

General Counsel

Pauline Kenny